In the present thesis, pharmacometric modelling methodologies were applied to determine the pharmacokinetics of sibrotuzumab, a humanised therapeutic monoclonal antibody, and to account for the in uence of immunogenicity. Furthermore, design factors in uencing the identi ability of model parameters characterising monoclonal antibody pharmacokinetics were investigated using a simulation-based approach.